Study of MX006 in Patients With Advanced and/or Metastatic Tumors known to express B7-H3
This study is looking at a new cancer drug called MX006. It is designed for adults with advanced or metastatic solid tumours—cancers that have grown or spread to other parts of the body—where cancer cells show a specific protein named B7-H3. Because this is a Phase 1 study, it is the very first time MX006 is being given to people. The main goal is not to prove how well the drug works yet, but to check its safety, see what side effects it might cause, and find the safest dose to use in future studies. Taking part is completely voluntary. If you join, doctors will closely monitor your health with regular hospital visits, blood tests, and scans while you receive the treatment.
At a glance
What is this study about?
When cancer spreads or reaches an advanced stage, standard treatments may stop working as well as doctors would like. Researchers are constantly looking for new ways to target cancer cells while sparing healthy tissue. This trial focuses on a new drug called MX006, which aims to target a protein known as B7-H3 that is often found on the surface of various solid cancer tumours.
This is a 'first-in-human' Phase 1 clinical trial. That means laboratory tests have shown promise, but scientists now need to understand how the drug behaves inside the human body. The team wants to learn how the body processes MX006, what kind of side effects it can cause, and what dose is both safe and potentially helpful.
Studies like this are crucial steps in finding new cancer treatments. While it is too early to know if MX006 will shrink tumours, the information gathered from participants will help doctors understand whether it can become a safe and useful treatment option in the future.
Key takeaways
- Tests a new cancer drug called MX006 for the first time in people.
- Open to adults aged 18 and over with advanced solid tumours containing the B7-H3 protein.
- Mainly focuses on checking the drug's safety, side effects, and finding the right dose.
- Requires frequent hospital visits, blood tests, and scans for careful monitoring.
- Participation is entirely voluntary and you can withdraw at any time.
Who may be eligible?
This trial is for adults aged 18 and older who have an advanced or metastatic solid tumour. A solid tumour is a cancer that forms a solid lump, such as in the lungs, breasts, bowel, or prostate, rather than blood cancers like leukaemia. To be considered, tests on your tumour must show that it produces a specific protein called B7-H3.
Usually, participants in early-stage trials have already tried standard NHS treatments, or there may be no suitable routine treatments left for their condition. You will also need to be reasonably active and well enough to attend frequent hospital appointments.
People with certain other medical issues, active severe infections, or those who are pregnant may not be able to join. The trial team will carry out detailed blood tests, scans, and health checks to make sure taking part is as safe as possible for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with an advanced or metastatic solid tumour.
- My tumour has been tested (or can be tested) for the B7-H3 protein.
- I have already tried standard treatments or have no routine options left.
- I am well enough to travel to regular hospital check-ups and appointments.
What does participation involve?
Taking part in this study involves receiving the study drug MX006 at a specialist hospital clinic. Because this is the first time the drug is being given to humans, you will need to attend regular clinic appointments so doctors can watch you very closely. These visits will include regular physical examinations, blood tests, heart checks (such as ECGs), and imaging scans like CT or MRI scans to monitor your tumour. You may need to spend several hours at the hospital on treatment days, especially during your first few doses. The study team will track your health throughout treatment and for a period of follow-up visits afterwards. Total participation time varies depending on how your body handles the medicine.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What does 'first-in-human' mean?
It means this is the first clinical trial where this specific medicine is being given to people, following tests in the laboratory.
What is B7-H3?
B7-H3 is a type of protein found on the surface of some cancer cells. The trial drug is designed to recognise and attach to this protein.
Will taking part cost me anything?
No, the study drug and all trial tests are provided free of charge. Some studies also help cover travel expenses to and from the hospital.
Can I leave the trial if I change my mind?
Yes, you can leave the study at any time without giving a reason, and your regular medical team will continue to care for you.
Will I definitely receive the study drug?
Yes, in Phase 1 safety studies of this type, all participants receive the experimental drug, often starting at low doses to test safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.